Femara contains letrozole, a non-steroidal aromatase inhibitor. It works by reducing aromatase activity, thereby lowering the conversion of androgens into estrogen.
Letrozole is primarily used for hormone-receptor-positive breast cancer, particularly in postmenopausal patients, with its role depending on the stage and clinical circumstances.
Lower estrogen levels can contribute to hot flashes, joint discomfort, and loss of bone mineral density. Treatment therefore requires consideration of bone health and other individual factors. Letrozole should be distinguished from selective estrogen receptor modulators because it reduces estrogen synthesis rather than primarily blocking estrogen receptors.
Reviews
There are no reviews yet.